Literature DB >> 10537899

The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies.

K Claxton1.   

Abstract

The literature which considers the statistical properties of cost-effectiveness analysis has focused on estimating the sampling distribution of either an incremental cost-effectiveness ratio or incremental net benefit for classical inference. However, it is argued here that rules of inference are arbitrary and entirely irrelevant to the decisions which clinical and economic evaluations claim to inform. Decisions should be based only on the mean net benefits irrespective of whether differences are statistically significant or fall outside a Bayesian range of equivalence. Failure to make decisions in this way by accepting the arbitrary rules of inference will impose costs which can be measured in terms of resources or health benefits forgone. The distribution of net benefit is only relevant to deciding whether more information is required. A framework for decision making and establishing the value of additional information is presented which is consistent with the decision rules in CEA. This framework can distinguish the simultaneous but conceptually separate steps of deciding which alternatives should be chosen, given existing information, from the question of whether more information should be acquired. It also ensures that the type of information acquired is driven by the objectives of the health care system, is consistent with the budget constraint on service provision and that research is designed efficiently.

Entities:  

Mesh:

Year:  1999        PMID: 10537899     DOI: 10.1016/s0167-6296(98)00039-3

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  211 in total

1.  Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration.

Authors:  Martin E Backhouse
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 2.  Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.

Authors:  Niklas Zethraeus; Magnus Johannesson; Bengt Jönsson; Mickael Löthgren; Magnus Tambour
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

Authors:  Laura McCullagh; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

4.  Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer.

Authors:  Laura McCullagh; Susanne Schmitz; Michael Barry; Cathal Walsh
Journal:  Pharmacoeconomics       Date:  2017-11       Impact factor: 4.981

5.  Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.

Authors:  Helen Dakin; Morris Sherman; Scott Fung; Carrie Fidler; Anthony Bentley
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

6.  Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program.

Authors:  Nadia Demarteau; Thomas Breuer; Baudouin Standaert
Journal:  Pharmacoeconomics       Date:  2012-04       Impact factor: 4.981

7.  Evidence-based medicine: excessive attraction to efficiency and certainty?

Authors:  Erik Nord
Journal:  Health Care Anal       Date:  2002

8.  Modeled cost-effectiveness of the Experience Corps Baltimore based on a pilot randomized trial.

Authors:  Kevin D Frick; Michelle C Carlson; Thomas A Glass; Sylvia McGill; George W Rebok; Crystal Simpson; Linda P Fried
Journal:  J Urban Health       Date:  2004-03       Impact factor: 3.671

Review 9.  Sample size determination for cost-effectiveness trials.

Authors:  Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

10.  Assessing the Clinical Impact of Risk Models for Opting Out of Treatment.

Authors:  Kathleen F Kerr; Marshall D Brown; Tracey L Marsh; Holly Janes
Journal:  Med Decis Making       Date:  2019-01-16       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.